title: Urokinase plasminogen activator regulates pulmonary arterial contractility and vascular permeability in mice.
abstract: The concentration of urokinase plasminogen activator (uPA) is elevated in pathological settings such as acute lung injury, where pulmonary arterial contractility and permeability are disrupted. uPA limits the accretion of fibrin after injury. Here we investigated whether uPA also regulates pulmonary arterial contractility and permeability. Contractility was measured using isolated pulmonary arterial rings. Pulmonary blood flow was measured in vivo by Doppler and pulmonary vascular permeability, according to the extravasation of Evans blue. Our data show that uPA regulates the in vitro pulmonary arterial contractility induced by phenylephrine in a dose-dependent manner through two receptor-dependent pathways, and regulates vascular contractility and permeability in vivo. Physiological concentrations of uPA (≤1 nM) stimulate the contractility of pulmonary arterial rings induced by phenylephrine through the low-density lipoprotein receptor-related protein receptor. The procontractile effect of uPA is independent of its catalytic activity. At pathophysiological concentrations, uPA (20 nM) inhibits contractility and increases vascular permeability. The inhibition of vascular contractility and increase of vascular permeability is mediated through a two-step process that involves docking to N-methyl-d-aspartate receptor-1 (NMDA-R1) on pulmonary vascular smooth muscle cells, and requires catalytic activity. Peptides that specifically inhibit the docking of uPA to NMDA-R, or the uPA variant with a mutated receptor docking site, abolished both the effects of uPA on vascular contractility and permeability, without affecting its catalytic activity. These data show that uPA, at concentrations found under pathological conditions, reduces pulmonary arterial contractility and increases permeability though the activation of NMDA-R1. The selective inhibition of NMDAR-1 activation by uPA can be accomplished without a loss of fibrinolytic activity.
authors: Department of Pathology, Laboratory Medicine, University of Pennsylvania, Philadelphia, 19104, USA.
authors: Taher
authors: T
authors: Nassar
authors: Serge
authors: S
authors: Yarovoi
authors: Rami Abu
authors: RA
authors: Fanne
authors: Otailah
authors: O
authors: Waked
authors: Timothy C
authors: TC
authors: Allen
authors: Steven
authors: S
authors: Idell
authors: Douglas B
authors: DB
authors: Cines
authors: Abd Al-Roof
authors: AA
authors: Higazi
references: J Clin Invest. 1996 Jan 1;97(1):232-7
references: 8550840
references: Toxicol Pathol. 2000 Mar-Apr;28(2):277-84
references: 10805145
references: Clin Chest Med. 1982 Jan;3(1):35-56
references: 7075161
references: J Clin Invest. 1989 Aug;84(2):695-705
references: 2788176
references: Blood. 2004 Feb 1;103(3):897-902
references: 14512309
references: Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10686-90
references: 1279689
references: J Immunol. 2000 Aug 1;165(3):1513-9
references: 10903758
references: J Clin Invest. 1996 Dec 15;98(12):2666-73
references: 8981909
references: Am J Respir Cell Mol Biol. 2004 Feb;30(2):139-44
references: 12855408
references: J Biol Chem. 2002 Oct 25;277(43):40499-504
references: 12171938
references: J Clin Invest. 1998 Sep 1;102(5):919-28
references: 9727060
references: Nat Med. 2001 Jan;7(1):59-64
references: 11135617
references: Crit Care Med. 2003 Apr;31(4 Suppl):S213-20
references: 12682443
references: Am J Med. 1976 Nov;61(5):585-9
references: 984062
references: J Neurotrauma. 2004 Sep;21(9):1204-11
references: 15453990
references: J Clin Invest. 2004 Jul;114(1):104-11
references: 15232617
references: Brain Res. 2008 Sep 22;1231:121-31
references: 18656457
references: Transl Res. 2007 Feb;149(2):70-5
references: 17240317
references: Am J Physiol. 1991 Oct;261(4 Pt 1):L240-8
references: 1928357
references: Brain Res Dev Brain Res. 2005 May 12;156(2):139-46
references: 16099300
references: Proc Natl Acad Sci U S A. 1996 May 14;93(10):4688-92
references: 8643465
references: Am J Physiol Heart Circ Physiol. 2006 Sep;291(3):H1351-9
references: 16489109
references: Am J Physiol Lung Cell Mol Physiol. 2008 Dec;295(6):L967-75
references: 18836029
references: FASEB J. 2000 Jul;14(10):1411-22
references: 10877834
references: J Cell Physiol. 1992 Feb;150(2):258-63
references: 1734031
references: J Cell Biol. 1990 Aug;111(2):743-55
references: 1696269
references: J Immunol. 2003 Jun 1;170(11):5644-51
references: 12759445
references: Blood. 1996 Jul 15;88(2):542-51
references: 8695802
references: J Cereb Blood Flow Metab. 2008 Jun;28(6):1212-21
references: 18334994
references: J Leukoc Biol. 2005 Oct;78(4):937-45
references: 16033814
references: Stroke. 2005 Oct;36(10):2265-9
references: 16141421
references: Thromb Haemost. 2009 Nov;102(5):983-92
references: 19888538
references: Am J Physiol Lung Cell Mol Physiol. 2009 Mar;296(3):L337-46
references: 19098125
references: Atherosclerosis. 2007 Dec;195(2):254-61
references: 17275828
references: N Engl J Med. 1990 Mar 29;322(13):890-7
references: 2314423
references: J Biol Chem. 1997 Oct 24;272(43):27053-7
references: 9341144
references: Semin Thromb Hemost. 2008 Jul;34(5):475-84
references: 18956288
references: Am J Respir Cell Mol Biol. 2010 Dec;43(6):703-11
references: 20097831
references: Resuscitation. 1986 Sep;14(1-2):23-32
references: 3024276
references: EXS. 1997;79:391-411
references: 9002228
references: J Clin Invest. 1996 Apr 15;97(8):1818-26
references: 8621764
references: New Horiz. 1994 Nov;2(4):566-74
references: 7804805